Marimed (MRMD) Cost of Revenue (2011 - 2026)

Marimed (MRMD) has reported Cost of Revenue for 16 consecutive years, with $25.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 9.0% year-over-year to $25.7 million in Q2 2026; TTM through Jun 2026 was $105.5 million, a 9.28% increase from a year earlier, with the FY2025 full-year figure at $101.9 million, up 7.2% from the prior year.
• Cost of Revenue was $25.7 million for Q2 2026 at Marimed, up from $24.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $31.1 million in Q4 2025 and troughed at $14.3 million in Q1 2022.
• A 5-year average of $22.2 million and a median of $22.4 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 36.6% in 2022 and gained 0.21% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $20.0 million in 2022, then climbed by 7.81% to $21.6 million in 2023, then advanced by 21.83% to $26.3 million in 2024, then rose by 18.46% to $31.1 million in 2025, then declined by 17.49% to $25.7 million in 2026.
• The last three Cost of Revenue figures came in at $25.7 million (Q2 2026), $24.2 million (Q1 2026), and $31.1 million (Q4 2025), per Business Quant data.